MoneyLion
NYSE:MLMoneyLion Inc. provides a digital financial platform. The company's platform offers access to banking, borrowing, and investing solutions for customers. Its principal products include roarmoney, a digital demand deposit account; instacash, a cash advance product that gives customers early access to their recurring income deposits; Credit Builder Plus; MoneyLion Investing, an online investment account that offers access to separately managed accounts invested based on model exchange-traded fund portfolios; and MoneyLion Crypto, an online cryptocurrency account. It also provides embedded finance marketplace connecting and matching consumers with real-time, personalized product, and service recommendations through its proprietary integrative technology; and offers creative media and marketing services to clients across industries through its media division. The company is headquartered in New York, New York.
Pearl River
CVE:PRHPearl River Holdings Limited, through its subsidiaries, engages in the manufacture and distribution of plastic products in China, Australia, and the United States. The company was incorporated in 1994 and is based in London, Canada.
Synthetic Biologics
NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.